Volume 27, Number 2—February 2021
Synopsis
Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020
, Kristen E. Marshall1, Emily McDonald, Stacey W. Martin, Jacqueline E. Tate, Claire M. Midgley, Marie E. Killerby, Breanna Kawasaki, Rachel K. Herlihy, Nisha B. Alden, J. Erin Staples, and on behalf of the Colorado Investigation Team2
Table 2
Frequency and duration of symptoms reported by 364 hospitalized and nonhospitalized patients with laboratory-confirmed coronavirus disease, Colorado, USA, March 2020*
| Symptoms | Hospitalized, n = 128 |
Nonhospitalized, n = 236 |
Crude OR (95% CI) | p value | |||
|---|---|---|---|---|---|---|---|
| No. (%) | Median symptom duration (IQR) | No. (%) | Median symptom duration (IQR) | ||||
| Symptom groups | |||||||
| Any general symptom† | 122 (95) | NC | 234 (99) | NC | NC | NC | |
| Any LRI symptom‡ | 116 (91) | NC | 213 (90) | NC | NC | NC | |
| Any cognitive or perception symptom§ | 87 (68) | NC | 165 (70) | NC | NC | NC | |
| Any URI symptom¶ | 60 (47) | NC | 158 (67) | NC | NC | NC | |
| Any GI symptom# |
74 (58) |
NC |
136 (58) |
NC |
NC |
NC |
|
| Individual symptoms | |||||||
| Fever** | 108 (84) | ** | 196 (83) | ** | 1.10 (0.61–2.01) | 0.74 | |
| Fatigue | 106 (83) | 14 (9–27) | 213 (90) | 12 (7–15) | 0.52 (0.28–0.98) | 0.04 | |
| Any cough†† | 93 (73) | NC | 196 (83) | NC | NC | NC | |
| Dry cough | 79 (62) | 10 (7–22) | 175 (74) | 10 (5–18) | 0.56 (0.35–0.89) | 0.01 | |
| Chills | 84 (66) | 7 (3–10) | 169 (72) | 3 (2–7) | 0.76 (0.48–1.20) | 0.24 | |
| Myalgia | 72 (56) | 11 (7–15) | 175 (74) | 5 (3–9) | 0.45 (0.28–0.71) | <0.01 | |
| Anorexia | 89 (70) | 12 (7–17) | 150 (64) | 7 (4–11) | 1.31 (0.83–2.09) | 0.25 | |
| Dyspnea | 92 (72) | 10 (5–19) | 144 (61) | 10 (6–14) | 1.63 (1.03–2.62) | 0.04 | |
| Headache | 66 (52) | 8 (4–14) | 166 (70) | 7 (3–14) | 0.45 (0.29–0.70) | <0.01 | |
| Ageusia | 63 (49) | 14 (8–21) | 149 (63) | 10 (7–20) | 0.57 (0.37–0.87) | 0.01 | |
| Sweats | 70 (55) | 7 (3–10) | 134 (57) | 3 (2–7) | 0.92 (0.60–1.42) | 0.70 | |
| Anosmia | 45 (35) | 14 (7–24) | 131 (56) | 10 (7–21) | 0.43 (0.28–0.67) | <0.01 | |
| Diarrhea | 60 (47) | 7 (3–13) | 104 (44) | 3 (2–6) | 1.12 (0.73–1.73) | 0.61 | |
| Arthralgia | 45 (35) | 13 (7–17) | 100 (42) | 5 (4–10) | 0.74 (0.47–1.15) | 0.18 | |
| Dehydration | 54 (42) | 10 (4–14) | 76 (32) | 5 (3–10) | 1.54 (0.98–2.40) | 0.06 | |
| Chest pain | 42 (33) | 10 (5–16) | 85 (36) | 7 (4–14) | 0.87 (0.55–1.36) | 0.54 | |
| Rhinorrhea | 31 (24) | 7 (3–12) | 97 (41) | 7 (4–14) | 0.46 (0.28–0.73) | <0.01 | |
| Sore throat | 28 (22) | 8 (4–15) | 91 (39) | 4 (2–7) | 0.45 (0.27–0.72) | <0.01 | |
| Nasal congestion | 28 (22) | 7 (3–14) | 86 (36) | 7 (5–14) | 0.49 (0.29–0.79) | <0.01 | |
| Nausea | 41 (32) | 7 (3–12) | 69 (29) | 4 (2–7) | 1.14 (0.71–1.81) | 0.58 | |
| Wheezing | 44 (34) | 12 (5–16) | 54 (23) | 9 (6–14) | 1.77 (1.10–2.84) | 0.02 | |
| Productive cough | 37 (29) | 10 (7–28) | 58 (25) | 10 (5–16) | 1.25 (0.77–2.02) | 0.37 | |
| Altered mental status | 39 (30) | 7 (3–16) | 39 (17) | 6 (3–12) | 2.21 (1.33–3.69) | <0.01 | |
| Abdominal pain | 18 (14) | 9 (7–20) | 49 (21) | 3 (2–5) | 0.62 (0.34–1.11) | 0.12 | |
| Conjunctivitis | 16 (13) | 7 (3–12) | 36 (15) | 5 (3–10) | 0.79 (0.41–1.47) | 0.47 | |
| Vomiting | 24 (19) | 4 (2–6) | 24 (10) | 2 (1–4) | 2.04 (1.10–3.77) | 0.02 | |
| Lymphadenopathy | 7 (5) | 7 (6–13) | 37 (16) | 6 (3–10) | 0.31 (0.12–0.68) | <0.01 | |
| Rash | 9 (7) | 4 (2–7) | 24 (10) | 5 (3–10) | 0.67 (0.29–1.44) | 0.32 | |
| Hemoptysis | 8 (6) | 7 (4–9) | 7 (3) | 3 (3–9) | 2.18 (0.77–6.36) | 0.14 | |
| Seizures | 3 (2) | 7 (4–10) | 0 | NC | NC | NC | |
*GI, gastrointestinal; IQR, interquartile range; LRI, lower respiratory tract infection; NC, not calculated; OR, odds ratio; URI, upper respiratory tract infection. †General symptoms included fever, chills, sweats, myalgia, headache, fatigue, arthralgia, dehydration, anorexia, and lymphadenopathy. ‡ LRI symptoms included cough (dry and productive), dyspnea, wheezing, hemoptysis, and chest pain. §Cognition and perception symptoms included anosmia, ageusia, and altered mental status. ¶URI symptoms included nasal congestion, rhinorrhea, and sore throat. #GI symptoms included nausea, vomiting, diarrhea, and abdominal pain. **Fever was collected individually as subjective or measured. Values were combined given potential bias because hospitalized patients were more likely to have their temperature measured compared with nonhospitalized patients, who more commonly reported subjective fever only. The median duration of both subjective and measured fevers in nonhospitalized patients was 4 d (IQR 2–7 d). In hospitalized patients, the median duration of measured fever was 7 d [IQR 3–11 d] and subjective fever was 8 d (IQR 4–13 d). ††Any cough is a combination of dry cough, productive cough, and hemoptysis, which are also reported individually.
1These authors contributed equally to this article.
2Members of the team are listed at the end of this article.